# US 2025/0320246 A1 · 3-azasteroid compounds for the treatment of diseases related to mitrochondrial function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0320246 A1
- Document ID: US20250320246A1
- Status: Published application
- Kind: A1
- Application number: 18/870,074
- Filed: 2023-06-01
- Published: 2025-10-16
- Earliest claimed: 2022-06-01
- Assignees: NZP UK Limited
- Applicants: Nzp UK Limited
- Inventors: Alexander Charles WEYMOUTH-WILSON; Laura Louise WALLIS; Gemma Louise PARKER; Heather MORTIBOYS; Oliver BANDMANN; Christopher HASTINGS; Louise Danielle HEYWOOD; Andreas LUXENBURGER; Lawrence Daniel HARRIS
- Web page: https://patentgrep.com/patent/US20250320246A1

## CPC

- C07J 73/005: {by nitrogen as hetero atom}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 39/00: General protective or antinoxious agents
- C07C 271/22: to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07C 2603/16: Benz[e]indenes; Hydrogenated benz[e]indenes
- C07J: STEROIDS (seco-steroids C07C)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Compounds of formula (I): wherein R1, R2 and R3 are as defined herein are able to rescue dysfunctional mitochondria and are therefore of use in the treatment and prevention of neurodegenerative disorders as well as acute radiation syndrome and myalgic encephalomyelitis (ME, chronic fatigue syndrome) or post viral syndrome, including chronic symptoms arising from infection with SARS-CoV2 (long COVID).

## Claims

### Claim at position 1

1-93. (canceled)

### Claim 94

A compound of formula (I):
wherein:
R1 is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C(O)R4 and —C(O)OR5, wherein alkyl, alkenyl and alkynyl R1 groups are optionally substituted with one or more substituents independently selected from OR11a and N(R11a)(R11b);
wherein each of R4 and R5 is independently C1-6 alkyl optionally substituted with one or more substituents selected from OR14a, N(R14a)(R14b), NH3+, C(O)N(R14a)(R14b), SR14 a 5- or 6-membered nitrogen-containing heterocyclic ring and a 6- to 14-membered aryl or 5- to 14-membered heteroaryl, wherein the aryl and heteroaryl are optionally substituted with one or more substituents selected from OH, halo, NH2, NO2, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(C1-6 alkyl) and O(C1-6 haloalkyl); and
R14a and R14b are each independently selected from H and C1-6 alkyl; and
wherein each of R11a and R11b is independently selected from H and C1-4 alkyl;
R2 is selected from O and OH, wherein when R2 is O, is a double bond and when R2 is OH, is a single bond;
R3 is selected from C(O)OH, C(O)OR16, C(O)N(R6)—X1—R7, C(O)N(R8)(R9) and C(O)S—R10;
R16 is selected from C1-8 alkyl optionally substituted with one or more substituents selected from OH, halo and phenyl, wherein phenyl is optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(C1-6 alkyl) O(C1-6 haloalkyl), O(R15a), N(R15a)(R15b) and C(O)N(R15a)(R15b);
wherein R15a and R15b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl;
X1 is C1-6 alkylene optionally substituted with one or more substituents selected from halo, OR12a, SR12a, N(R12a)(R12b) C(O)OR12a, C(O)N(R12a)(R12b), N(R12a)—C(NH)—N(R12a)(R12b), N(R12a)—C(N+H2)—N(R12a)(R12b) and 6- to 14-membered aryl or 5- to 14-membered heteroaryl, wherein aryl and heteroaryl groups are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, C1-6 haloalkyl OR13a, N(R13a)(R13b), NO2, S(O)2OH, and CN;
R12a and R12b are each independently selected from H and C1-6 alkyl;
R13a and R13b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl;
R6 is selected from H, methyl and ethyl;
R7 is selected from C(O)OH, C(O)O—(C1-6 alkyl), S(O)2OH, and S(O)2—O—(C1-6 alkyl);
R8 is selected from H, C1-6 alkyl and a 3- to 6-membered carbocyclyl group optionally substituted with one or more substituents selected from C1-6 alkyl, OH, O—(C1-6 alkyl), N(R19a)(R19b), C1-6 haloalkyl and halo;
wherein R19a and R19b are each independently selected from H and C1-6 alkyl;
R9 is selected from H, C1-6 alkyl, a 3- to 7-membered carbocyclyl group, a 3- to 7-membered heterocyclyl group, 6- to 14-membered aryl and 5- to 14-membered heteroaryl;
wherein alkyl groups are optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), C1-4 haloalkyl, O—(C1-4 haloalkyl), halo, N(R19a)(R19b), phenyl, 3- to 7-membered carbocyclyl and 3- to 7-membered heterocyclyl;
wherein R19a and R19b are each independently as defined above;
wherein carbocyclyl and heterocyclyl groups are optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), C1-4 haloalkyl, O—(C1-4 haloalkyl), oxo, phenyl, benzyl and halo, provided that heteroatoms of a heterocyclyl group are not substituted with OH, O—(C1-4 alkyl) or O—(C1-4 haloalkyl); and
wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b), C(O)N(R15a)(R15b), C(O)OH and C(O)O—(C1-6 alkyl);
wherein R15a and R15b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl; or
R8 and R9 together with the nitrogen atom to which they are attached combine to form a 4- to 10-membered heterocyclic group, optionally containing one or more further heteroatoms selected from O, N and S and optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), halo, C1-4 haloalkyl, O—(C1-4 haloalkyl), C(O)OH, C(O)O(C1-4 alkyl), phenyl, benzyl, CN, N(R15a)(R15b), C(O)N(R15a)(R15b) and oxo provided that heteroatoms of a heterocyclyl group are not substituted with CN, N(R15a)(R15b), OH, O—(C1-4 alkyl) or O—(C1-4 haloalkyl);
wherein alkyl groups are optionally substituted by one or more groups selected from O—(C1-4 alkyl), O—(C1-4 haloalkyl), N(R15a)(R15b), OH and C3-6 cycloalkyl; or
R8 and R9 together with the nitrogen atom to which they are attached combine to form a 5- to 10-membered heteroaryl group optionally containing one or more further heteroatoms selected from N, O and S and optionally substituted with one or more substituents selected halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b), C(O)OH, C(O)N(R15a)(R15b) and C(O)O—(C1-6 alkyl);
wherein R15a and R15b are each independently as defined above;
wherein alkyl groups are optionally substituted by one or more groups selected from OH and C3-6 cycloalkyl;
wherein when the heteroaryl group contains a non-aromatic ring, the non-aromatic ring may also be substituted with oxo;
R10 is C1-6 alkyl optionally substituted with OH, halo or phenyl, wherein phenyl is optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b) and C(O)N(R15a)(R15b);
wherein R15a and R15b are each independently as defined above; and
n is 1 or 2;
or a salt or solvate thereof.

### Claim 95 (depends on 94)

A compound, salt or solvate according to claim 94, wherein is a single bond and the compound is a compound of formula (IA) or (IB):
wherein
R1 is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C(O)R4 and —C(O)OR5, wherein alkyl, alkenyl and alkynyl R1 groups are optionally substituted with one or more substituents independently selected from OR11a and N(R11a)(R11b);
wherein each of R4 and R5 is independently C1-6 alkyl optionally substituted with one or more substituents selected from OR14a, N(R14a)(R14b), NH3+, C(O)N(R14a)(R14b), SR14 a 5- or 6-membered nitrogen-containing heterocyclic ring and a 6- to 14-membered aryl or 5- to 14-membered heteroaryl, wherein the aryl and heteroaryl are optionally substituted with one or more substituents selected from OH, halo, NH2, NO2, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(C1-6 alkyl) and O(C1-6 haloalkyl); and
R14a and R14b are each independently selected from H and C1-6 alkyl; and
wherein each of R11a and R11b is independently selected from H and C1-4 alkyl;
R3 is selected from C(O)OH, C(O)OR16, C(O)N(R6)—X1—R7, C(O)N(R8)(R9) and C(O)S—R10;
R16 is selected from C1-8 alkyl optionally substituted with one or more substituents selected from OH, halo and phenyl, wherein phenyl is optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(C1-6 alkyl) O(C1-6 haloalkyl), O(R15a), N(R15a)(R15b) and C(O)N(R15a)(R15b);
wherein R15a and R15b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl;
X1 is C1-6 alkylene optionally substituted with one or more substituents selected from halo, OR12a, SR12a, N(R12a)(R12b) C(O)OR12a, C(O)N(R12a)(R12b), N(R12a)—C(NH)—N(R12a)(R12b), N(R12a)—C(N+H2)—N(R12a)(R12b) and 6- to 14-membered aryl or 5- to 14-membered heteroaryl, wherein aryl and heteroaryl groups are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, C1-6 haloalkyl OR13a, N(R13a)(R13b), NO2, S(O)2OH, and CN;
R12a and R12b are each independently selected from H and C1-6 alkyl;
R13a and R13b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl;
R6 is selected from H, methyl and ethyl;
R7 is selected from C(O)OH, C(O)O—(C1-6 alkyl), S(O)2OH, and S(O)2—O—(C1-6 alkyl);
R8 is selected from H, C1-6 alkyl and a 3- to 6-membered carbocyclyl group optionally substituted with one or more substituents selected from C1-6 alkyl, OH, O—(C1-6 alkyl), N(R19a)(R19b), C1-6 haloalkyl and halo;
wherein R19a and R19b are each independently selected from H and C1-6 alkyl;
R9 is selected from H, C1-6 alkyl, a 3- to 7-membered carbocyclyl group, a 3- to 7-membered heterocyclyl group, 6- to 14-membered aryl and 5- to 14-membered heteroaryl;
wherein alkyl groups are optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), C1-4 haloalkyl, O—(C1-4 haloalkyl), halo, N(R19a)(R19b), phenyl, 3- to 7-membered carbocyclyl and 3- to 7-membered heterocyclyl;
wherein R19a and R19b are each independently as defined above;
wherein carbocyclyl and heterocyclyl groups are optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), C1-4 haloalkyl, O—(C1-4 haloalkyl), oxo, phenyl, benzyl and halo, provided that heteroatoms of a heterocyclyl group are not substituted with OH, O—(C1-4 alkyl) or O—(C1-4 haloalkyl); and
wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b), C(O)N(R15a)(R15b), C(O)OH and C(O)O—(C1-6 alkyl);
wherein R15a and R15b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl; or
R8 and R9 together with the nitrogen atom to which they are attached combine to form a 4- to 10-membered heterocyclic group, optionally containing one or more further heteroatoms selected from O, N and S and optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), halo, C1-4 haloalkyl, O—(C1-4 haloalkyl), C(O)OH, C(O)O(C1-4 alkyl), phenyl, benzyl, CN, N(R15a)(R15b), C(O)N(R15a)(R15b) and oxo provided that heteroatoms of a heterocyclyl group are not substituted with CN, N(R15a)(R15b), OH, O—(C1-4 alkyl) or O—(C1-4 haloalkyl);
wherein alkyl groups are optionally substituted by one or more groups selected from O—(C1-4 alkyl), O—(C1-4 haloalkyl), N(R15a)(R15b), OH and C3-6 cycloalkyl; or
R8 and R9 together with the nitrogen atom to which they are attached combine to form a 5- to 10-membered heteroaryl group optionally containing one or more further heteroatoms selected from N, O and S and optionally substituted with one or more substituents selected halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b), C(O)OH, C(O)N(R15a)(R15b) and C(O)O—(C1-6 alkyl);
wherein R15a and R15b are each independently as defined above;
wherein alkyl groups are optionally substituted by one or more groups selected from OH and C3-6 cycloalkyl;
wherein when the heteroaryl group contains a non-aromatic ring, the non-aromatic ring may also be substituted with oxo;
R10 is C1-6 alkyl optionally substituted with OH, halo or phenyl, wherein phenyl is optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b) and C(O)N(R15a)(R15b);
wherein R15a and R15b are each independently as defined above; and
n is 1 or 2.

### Claim 96 (depends on 94)

A compound, salt or solvate according to claim 94, wherein is a double bond and the compound is a compound of formula (IC):
wherein
R1 is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C(O)R4 and —C(O)OR5, wherein alkyl, alkenyl and alkynyl R1 groups are optionally substituted with one or more substituents independently selected from OR11a and N(R11a)(R11b);
wherein each of R4 and R5 is independently C1-6 alkyl optionally substituted with one or more substituents selected from OR14a, N(R14a)(R14b), NH3+, C(O)N(R14a)(R14b), SR14 a 5- or 6-membered nitrogen-containing heterocyclic ring and a 6- to 14-membered aryl or 5- to 14-membered heteroaryl, wherein the aryl and heteroaryl are optionally substituted with one or more substituents selected from OH, halo, NH2, NO2, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(C1-6 alkyl) and O(C1-6 haloalkyl); and
R14a and R14b are each independently selected from H and C1-6 alkyl; and
wherein each of R11a and R11b is independently selected from H and C1-4 alkyl;
R3 is selected from C(O)OH, C(O)OR16, C(O)N(R6)—X1—R7, C(O)N(R8)(R9) and C(O)S—R10;
R16 is selected from C1-8 alkyl optionally substituted with one or more substituents selected from OH, halo and phenyl, wherein phenyl is optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(C1-6 alkyl) O(C1-6 haloalkyl), O(R15a), N(R15a)(R15b) and C(O)N(R15a)(R15b);
wherein R15a and R15b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl;
X1 is C1-6 alkylene optionally substituted with one or more substituents selected from halo, OR12a, SR12a, N(R12a)(R12b) C(O)OR12a, C(O)N(R12a)(R12b) N(R12a)—C(NH)—N(R12a)(R12b), N(R12a)—C(N+H2)—N(R12a)(R12b) and 6- to 14-membered aryl or 5- to 14-membered heteroaryl, wherein aryl and heteroaryl groups are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, C1-6 haloalkyl OR13a, N(R13a)(R13b), NO2, S(O)2OH, and CN;
R12a and R12b are each independently selected from H and C1-6 alkyl;
R13a and R13b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl;
R6 is selected from H, methyl and ethyl;
R7 is selected from C(O)OH, C(O)O—(C1-6 alkyl), S(O)2OH, and S(O)2—O—(C1-6 alkyl);
R8 is selected from H, C1-6 alkyl and a 3- to 6-membered carbocyclyl group optionally substituted with one or more substituents selected from C1-5 alkyl, OH, O—(C1-5 alkyl), N(R19a)(R19b), C1-6 haloalkyl and halo;
wherein R19a and R19b are each independently selected from H and C1-6 alkyl;
R9 is selected from H, C1-6 alkyl, a 3- to 7-membered carbocyclyl group, a 3- to 7-membered heterocyclyl group, 6- to 14-membered aryl and 5- to 14-membered heteroaryl;
wherein alkyl groups are optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), C1-4 haloalkyl, O—(C1-4 haloalkyl), halo, N(R19a)(R19b), phenyl, 3- to 7-membered carbocyclyl and 3- to 7-membered heterocyclyl;
wherein R19a and R19b are each independently as defined above;
wherein carbocyclyl and heterocyclyl groups are optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), C1-4 haloalkyl, O—(C1-4 haloalkyl), oxo, phenyl, benzyl and halo, provided that heteroatoms of a heterocyclyl group are not substituted with OH, O—(C1-4 alkyl) or O—(C1-4 haloalkyl); and
wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b), C(O)N(R15a)(R15b), C(O)OH and C(O)O—(C1-6 alkyl);
wherein R15a and R15b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl; or
R8 and R9 together with the nitrogen atom to which they are attached combine to form a 4- to 10-membered heterocyclic group, optionally containing one or more further heteroatoms selected from O, N and S and optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), halo, C1-4 haloalkyl, O—(C1-4 haloalkyl), C(O)OH, C(O)O(C1-4 alkyl), phenyl, benzyl, CN, N(R15a)(R15b), C(O)N(R15a)(R15b) and oxo provided that heteroatoms of a heterocyclyl group are not substituted with CN, N(R15a)(R15b), OH, O—(C1-4 alkyl) or O—(C1-4 haloalkyl);
wherein alkyl groups are optionally substituted by one or more groups selected from O—(C1-4 alkyl), O—(C1-4 haloalkyl), N(R15a)(R15b), OH and C3-6 cycloalkyl; or
R8 and R9 together with the nitrogen atom to which they are attached combine to form a 5- to 10-membered heteroaryl group optionally containing one or more further heteroatoms selected from N, O and S and optionally substituted with one or more substituents selected halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b), C(O)OH, C(O)N(R15a)(R15b) and C(O)O—(C1-5 alkyl);
wherein R15a and R15b are each independently as defined above;
wherein alkyl groups are optionally substituted by one or more groups selected from OH and C3-6 cycloalkyl;
wherein when the heteroaryl group contains a non-aromatic ring, the non-aromatic ring may also be substituted with oxo;
R10 is C1-6 alkyl optionally substituted with OH, halo or phenyl, wherein phenyl is optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b) and C(O)N(R15a)(R15b);
wherein R15a and R15b are each independently as defined above; and
n is 1 or 2.

### Claim 97 (depends on 94)

A compound, salt or solvate according to claim 94, wherein R1 is H, methyl or ethyl.

### Claim 98 (depends on 94)

A compound, salt or solvate according to claim 94, wherein R1 is —C(O)R4, wherein R4 is selected from C1-6 alkyl optionally substituted with one or more substituents selected from OH, NH2, NH3′, phenyl optionally substituted with one or more substituents selected from OH and halo, and a nitrogen-containing heteroaryl group selected from pyrrole, pyridine and indole, optionally substituted with one or more substituents selected from OH and halo.

### Claim 99 (depends on 98)

A compound, salt or solvate according to claim 98, wherein R1 is an amino acid residue selected from residues of glycine, valine, isoleucine, leucine, tryptophan and tyrosine and salts of these amino acid residues.

### Claim 100 (depends on 94)

A compound, salt or solvate according to claim 94, wherein R1 is —C(O)OR5 wherein R5 is selected from C1-6 alkyl, benzyl or fluorenylmethyl.

### Claim 101 (depends on 94)

A compound, salt or solvate according to claim 94, which is a salt of formula (ID), (IE), (IF) or (IG):
wherein:
R1 is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C(O)R4 and —C(O)OR5, wherein alkyl, alkenyl and alkynyl R1 groups are optionally substituted with one or more substituents independently selected from OR11a and N(R11a)(R11b);
wherein each of R4 and R5 is independently C1-6 alkyl optionally substituted with one or more substituents selected from OR14a, N(R14a)(R14b), NH3+, C(O)N(R14a)(R14b), SR14 a 5- or 6-membered nitrogen-containing heterocyclic ring and a 6- to 14-membered aryl or 5- to 14-membered heteroaryl, wherein the aryl and heteroaryl are optionally substituted with one or more substituents selected from OH, halo, NH2, NO2, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(C1-6 alkyl) and O(C1-6 haloalkyl); and
R14a and R14b are each independently selected from H and C1-6 alkyl; and
wherein each of R11a and R11b is independently selected from H and C1-4 alkyl;
R2 is selected from O and OH, wherein when R2 is O, is a double bond and when R2 is OH, is a single bond;
R3 is selected from C(O)OH, C(O)OR16, C(O)N(R6)—X1—R7, C(O)N(R8)(R9) and C(O)S—R10;
R16 is selected from C1-8 alkyl optionally substituted with one or more substituents selected from OH, halo and phenyl, wherein phenyl is optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(C1-6 alkyl) O(C1-6 haloalkyl), O(R15a), N(R15a)(R15b) and C(O)N(R15a)(R15b);
wherein R15a and R15b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl;
X1 is C1-6 alkylene optionally substituted with one or more substituents selected from halo, OR12a, SR12a, N(R12a)(R12b) C(O)OR12a, C(O)N(R12a)(R12b), N(R12a)—C(NH)—N(R12a)(R12b), N(R12a)—C(N+H2)—N(R12a)(R12b) and 6- to 14-membered aryl or 5- to 14-membered heteroaryl, wherein aryl and heteroaryl groups are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, C1-6 haloalkyl OR13a, N(R13a)(R13b), NO2, S(O)2OH, and CN;
R12a and R12b are each independently selected from H and C1-6 alkyl;
R13a and R13b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl;
R6 is selected from H, methyl and ethyl;
R7 is selected from C(O)OH, C(O)O—(C1-6 alkyl), S(O)2OH, and S(O)2—O—(C1-6 alkyl);
R8 is selected from H, C1-6 alkyl and a 3- to 6-membered carbocyclyl group optionally substituted with one or more substituents selected from C1-6 alkyl, OH, O—(C1-6 alkyl), N(R19a)(R19b), C1-6 haloalkyl and halo;
wherein R19a and R19b are each independently selected from H and C1-6 alkyl;
R9 is selected from H, C1-6 alkyl, a 3- to 7-membered carbocyclyl group, a 3- to 7-membered heterocyclyl group, 6- to 14-membered aryl and 5- to 14-membered heteroaryl;
wherein alkyl groups are optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), C1-4 haloalkyl, O—(C1-4 haloalkyl), halo, N(R19a)(R19b), phenyl, 3- to 7-membered carbocyclyl and 3- to 7-membered heterocyclyl;
wherein R19a and R19b are each independently as defined above;
wherein carbocyclyl and heterocyclyl groups are optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), C1-4 haloalkyl, O—(C1-4 haloalkyl), oxo, phenyl, benzyl and halo, provided that heteroatoms of a heterocyclyl group are not substituted with OH, O—(C1-4 alkyl) or O—(C1-4 haloalkyl); and
wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b), C(O)N(R15a)(R15b), C(O)OH and C(O)O—(C1-6 alkyl);
wherein R15a and R15b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl; or
R8 and R9 together with the nitrogen atom to which they are attached combine to form a 4- to 10-membered heterocyclic group, optionally containing one or more further heteroatoms selected from O, N and S and optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), halo, C1-4 haloalkyl, O—(C1-4 haloalkyl), C(O)OH, C(O)O(C1-4 alkyl), phenyl, benzyl, CN, N(R15a)(R15b), C(O)N(R15a)(R15b) and oxo provided that heteroatoms of a heterocyclyl group are not substituted with CN, N(R15a)(R15b), OH, O—(C1-4 alkyl) or O—(C1-4 haloalkyl);
wherein alkyl groups are optionally substituted by one or more groups selected from O—(C1-4 alkyl), O—(C1-4 haloalkyl), N(R15a)(R15b), OH and C3-6 cycloalkyl; or
R8 and R9 together with the nitrogen atom to which they are attached combine to form a 5- to 10-membered heteroaryl group optionally containing one or more further heteroatoms selected from N, O and S and optionally substituted with one or more substituents selected halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b), C(O)OH, C(O)N(R15a)(R15b) and C(O)O—(C1-6 alkyl);
wherein R15a and R15b are each independently as defined above;
wherein alkyl groups are optionally substituted by one or more groups selected from OH and C3-6 cycloalkyl;
wherein when the heteroaryl group contains a non-aromatic ring, the non-aromatic ring may also be substituted with oxo;
R10 is C1-6 alkyl optionally substituted with OH, halo or phenyl, wherein phenyl is optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b) and C(O)N(R15a)(R15b);
wherein R15a and R15b are each independently as defined above; and
n is 1 or 2;
wherein the salt comprises a counterion Z− selected from chloride, trifluoroacetate, mesylate, bromide, sulphate, and fumarate is present.

### Claim 102 (depends on 94)

A compound, salt or solvate according to claim 94, wherein n is 1.

### Claim 103 (depends on 94)

A compound, salt or solvate according to claim 94, wherein n is 2.

### Claim 104 (depends on 94)

A compound, salt or solvate according to claim 94, wherein R3 is C(O)OH or C(O)O(C1-4 alkyl).

### Claim 105 (depends on 94)

A compound, salt or solvate according to claim 94, wherein R3 is C(O)N(R6)—X1—R7, wherein R6 is H or methyl; and wherein X1 is unsubstituted or substituted with one or more substituents selected from fluoro, OH, methoxy, ethoxy, i-propyloxy, s-butyloxy, t-butyloxy, S-methyl, NH2, C(O)OH, phenyl and phenyl substituted with OH; and
wherein R7 is selected from C(O)OH, C(O)O—(C1-3 alkyl) and S(O)2OH.

### Claim 106 (depends on 94)

A compound, salt or solvate according to claim 94 wherein R3 is C(O)N(R8)(R9), where:
R8 is selected from H, C1-6 alkyl and a 3- to 6-membered carbocyclyl group optionally substituted with one or more substituents selected from C1-6 alkyl, OH, O—(C1-6 alkyl), N(R19a)(R19b), C1-6 haloalkyl and halo;
wherein R19a and R19b are each independently selected from H and C1-6 alkyl;
R9 is selected from H, C1-6 alkyl, a 3- to 7-membered carbocyclyl group, a 3- to 7-membered heterocyclyl group, 6- to 14-membered aryl and 5- to 14-membered heteroaryl;
wherein alkyl groups are optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), C1-4 haloalkyl, O—(C1-4 haloalkyl), halo, N(R19a)(R19b), phenyl, 3- to 7-membered carbocyclyl and 3- to 7-membered heterocyclyl;
wherein R19a and R19b are each independently as defined above;
wherein carbocyclyl and heterocyclyl groups are optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), C1-4 haloalkyl, O—(C1-4 haloalkyl), oxo, phenyl, benzyl and halo, provided that heteroatoms of a heterocyclyl group are not substituted with OH, O—(C1-4 alkyl) or O—(C1-4 haloalkyl); and
wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b), C(O)N(R15a)(R15b), C(O)OH and C(O)O—(C1-6 alkyl);
wherein R15a and R15b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl; or
R8 and R9 together with the nitrogen atom to which they are attached combine to form a 4- to 10-membered heterocyclic group, optionally containing one or more further heteroatoms selected from O, N and S and optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), halo, C1-4 haloalkyl, O—(C1-4 haloalkyl), C(O)OH, C(O)O(C1-4 alkyl), phenyl, benzyl, CN, N(R15a)(R15b), C(O)N(R15a)(R15b) and oxo provided that heteroatoms of a heterocyclyl group are not substituted with CN, N(R15a)(R15b), OH, O—(C1-4 alkyl) or O—(C1-4 haloalkyl);
wherein alkyl groups are optionally substituted by one or more groups selected from O—(C1-4 alkyl), O—(C1-4 haloalkyl), N(R15a)(R15b), OH and C3-6 cycloalkyl; or
R8 and R9 together with the nitrogen atom to which they are attached combine to form a 5- to 10-membered heteroaryl group optionally containing one or more further heteroatoms selected from N, O and S and optionally substituted with one or more substituents selected halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b), C(O)OH, C(O)N(R15a)(R15b) and C(O)O—(C1-6 alkyl);
wherein R15a and R15b are each independently as defined above;
wherein alkyl groups are optionally substituted by one or more groups selected from OH and C3-6 cycloalkyl;
wherein when the heteroaryl group contains a non-aromatic ring, the non-aromatic ring may also be substituted with oxo.

### Claim 107 (depends on 106)

A compound, salt or solvate according to claim 106, wherein R8 is selected from H, methyl, ethyl, unsubstituted cyclopentyl and unsubstituted cyclohexyl.

### Claim 108 (depends on 106)

A compound, salt or solvate according to claim 106, wherein R8 is H and R9 is methyl, which is unsubstituted or substituted with a 5- or 6-membered heterocyclyl group selected from morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl and tetrahydrofuryl, wherein the heterocyclyl group is unsubstituted or substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), C1-4 haloalkyl, O—(C1-4 haloalkyl), oxo, phenyl, benzyl and halo, provided that heteroatoms of a heterocyclyl group are not substituted with OH, O—(C1-4 alkyl) or O—(C1-4 haloalkyl).

### Claim 109 (depends on 106)

A compound, salt or solvate according to claim 106, wherein R9 is selected from:
a carbocyclyl group selected from cyclopentyl and cyclohexyl; a heterocyclyl group selected from pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl wherein the heterocyclyl group is unsubstituted or substituted with oxo;
phenyl or naphthyl wherein phenyl or naphthyl is unsubstituted or substituted with one or more substituents selected from halo, C(O)OH and C(O)O—(C1-4 alkyl); and
pyridyl which is unsubstituted or substituted with one or more substituents selected from halo, C(O)OH and C(O)O—(C1-4 alkyl).

### Claim 110 (depends on 109)

A compound, salt or solvate according to claim 109, wherein R8 is H.

### Claim 111 (depends on 94, 109)

A compound, salt or solvate according to claim 109, wherein R8 and R9 together with the nitrogen atom to which they are attached combine to form a 4- to 10-membered heterocyclic group wherein:
the heterocyclic group is selected from piperidine, pyrrolidine, piperazine, morpholine and isothiazolidine, and is unsubstituted or is substituted as defined in claim 94; or
wherein the heterocyclic group comprises two rings, which are fused or bridged or joined by a spiro linkage; or
wherein the heterocyclic group is a piperidone or a pyrrolidone ring.

### Claim 112 (depends on 109)

A compound, salt or solvate according to claim 109, wherein R8 and R9 together with the nitrogen atom to which they are attached combine to form a 5- to 10-membered heteroaryl group optionally containing one or more further heteroatoms selected from N, O and S, wherein the heteroaryl group is unsubstituted or is substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b), C(O)OH and C(O)O—(C1-6 alkyl).

### Claim 113 (depends on 94)

A compound, salt or solvate according to claim 94, wherein R3 is C(O)S—R10, where R10 is selected from C1-6 alkyl optionally substituted with OH, halo or phenyl.

### Claim 114 (depends on 94)

A compound, salt or solvate according to claim 94, wherein R2 is OH, R3 is C(O)OH and the compound is of formula (IH) or a salt of formula (IJ):
where R1 is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C(O)R4 and —C(O)OR5, wherein alkyl, alkenyl and alkynyl R1 groups are optionally substituted with one or more substituents independently selected from OR11a and N(R11a)(R11b);
wherein each of R4 and R5 is independently C1-6 alkyl optionally substituted with one or more substituents selected from OR14a, N(R14a)(R14b), NH3+, C(O)N(R14a)(R14b), SR14 a 5- or 6-membered nitrogen-containing heterocyclic ring and a 6- to 14-membered aryl or 5- to 14-membered heteroaryl, wherein the aryl and heteroaryl are optionally substituted with one or more substituents selected from OH, halo, NH2, NO2, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(C1-6 alkyl) and O(C1-6 haloalkyl); and
R14a and R14b are each independently selected from H and C1-6 alkyl; and
wherein each of R11a and R11b is independently selected from H and C1-4 alkyl;
or
wherein R1 is H, R2 is OH and n is 1 and the compound is of formula (IK) or a salt of formula (IL)
where R3 is selected from C(O)OH, C(O)OR16, C(O)N(R6)—X1—R7, C(O)N(R8)(R9) and C(O)S—R10;
R16 is selected from C1-8 alkyl optionally substituted with one or more substituents selected from OH, halo and phenyl, wherein phenyl is optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(C1-6 alkyl) O(C1-6 haloalkyl), O(R15a), N(R15a)(R15b) and C(O)N(R15a)(R15b);
wherein R15a and R15b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl;
X1 is C1-6 alkylene optionally substituted with one or more substituents selected from halo, OR12a, SR12a, N(R12a)(R12b) C(O)OR12a, C(O)N(R12a)(R12b), N(R12a)—C(NH)—N(R12a)(R12b), N(R12a)—C(N+H2)—N(R12a)(R12b) and 6- to 14-membered aryl or 5- to 14-membered heteroaryl, wherein aryl and heteroaryl groups are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, C1-6 haloalkyl OR13a, N(R13a)(R13b), NO2, S(O)2OH, and CN;
R12a and R12b are each independently selected from H and C1-6 alkyl;
R13a and R13b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl;
R6 is selected from H, methyl and ethyl;
R7 is selected from C(O)OH, C(O)O—(C1-6 alkyl), S(O)2OH, and S(O)2—O—(C1-6 alkyl);
R8 is selected from H, C1-6 alkyl and a 3- to 6-membered carbocyclyl group optionally substituted with one or more substituents selected from C1-6 alkyl, OH, O—(C1-6 alkyl), N(R19a)(R19b), C1-6 haloalkyl and halo;
wherein R19a and R19b are each independently selected from H and C1-6 alkyl;
R9 is selected from H, C1-6 alkyl, a 3- to 7-membered carbocyclyl group, a 3- to 7-membered heterocyclyl group, 6- to 14-membered aryl and 5- to 14-membered heteroaryl;
wherein alkyl groups are optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), C1-4 haloalkyl, O—(C1-4 haloalkyl), halo, N(R19a)(R19b), phenyl, 3- to 7-membered carbocyclyl and 3- to 7-membered heterocyclyl;
wherein R19a and R19b are each independently as defined above;
wherein carbocyclyl and heterocyclyl groups are optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), C1-4 haloalkyl, O—(C1-4 haloalkyl), oxo, phenyl, benzyl and halo, provided that heteroatoms of a heterocyclyl group are not substituted with OH, O—(C1-4 alkyl) or O—(C1-4 haloalkyl); and
wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b), C(O)N(R15a)(R15b), C(O)OH and C(O)O—(C1-6 alkyl);
wherein R15a and R15b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl; or
R8 and R9 together with the nitrogen atom to which they are attached combine to form a 4- to 10-membered heterocyclic group, optionally containing one or more further heteroatoms selected from O, N and S and optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), halo, C1-4 haloalkyl, O—(C1-4 haloalkyl), C(O)OH, C(O)O(C1-4 alkyl), phenyl, benzyl, CN, N(R15a)(R15b), C(O)N(R15a)(R15b) and oxo provided that heteroatoms of a heterocyclyl group are not substituted with CN, N(R15a)(R15b), OH, O—(C1-4 alkyl) or O—(C1-4 haloalkyl);
wherein alkyl groups are optionally substituted by one or more groups selected from O—(C1-4 alkyl), O—(C1-4 haloalkyl), N(R15a)(R15b), OH and C3-6 cycloalkyl; or
R8 and R9 together with the nitrogen atom to which they are attached combine to form a 5- to 10-membered heteroaryl group optionally containing one or more further heteroatoms selected from N, O and S and optionally substituted with one or more substituents selected halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b), C(O)OH, C(O)N(R15a)(R15b) and C(O)O—(C1-6 alkyl);
wherein R15a and R15b are each independently as defined above;
wherein alkyl groups are optionally substituted by one or more groups selected from OH and C3-6 cycloalkyl;
wherein when the heteroaryl group contains a non-aromatic ring, the non-aromatic ring may also be substituted with oxo;
R10 is C1-6 alkyl optionally substituted with OH, halo or phenyl, wherein phenyl is optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b) and C(O)N(R15a)(R15b);
wherein R15a and R15b are each independently as defined above.

### Claim 115 (depends on 94)

A compound according to claim 94, selected from:
tert-Butyl N-(benzyloxycarbony)-3-aza-7β-hydroxy-5β-cholan-24-oate (25a);
tert-Butyl 3-aza-7β-hydroxy-5β-cholan-24-oate (27a);
3-Aza-7β-hydroxy-5β-cholan-24-oic acid (28a);
tert-Butyl N-methyl-3-aza-7β-hydroxy-5β-cholan-24-oate (29a);
N-Methyl-3-aza-7β-hydroxy-5β-cholan-24-oic acid (31a and 33);
tert-Butyl N-ethyl-3-aza-7β-hydroxy-5β-cholan-24-oate (30);
N-Ethyl-3-aza-7β-hydroxy-5β-cholan-24-oic acid (32);
tert-Butyl N-glycolyl-3-aza-7β-hydroxy-5β-cholan-24-oate (34a);
N-Glycolyl-3-aza-7β-hydroxy-5β-cholan-24-oic acid (40a);
N-[(2S)-2-amino-3-methylbutanoyl]-3-aza-7β-hydroxy-5β-cholan-24-oic acid (41a);
N-[(2S,3S)-2-Amino-3-methylpentanoyl]-3-aza-7β-hydroxy-5β-cholan-24-oic acid (42a);
N-[(2S)-2-Amino-4-methylpentanoyl]-3-aza-7β-hydroxy-5β-cholan-24-oic acid (43a);
N-[(2S)-2-Amino-3-(1H-indol-3-yl)propanoyl]-3-aza-7β-hydroxy-5β-cholan-24-oic acid (44a);
N-[(2S)-2-Amino-3-(4-hydroxyphenyl)propanoyl]-3-aza-7β-hydroxy-5β-cholan-24-oic acid (45a);
tert-Butyl N-(benzyloxycarbonyl)-3-aza-7β-hydroxy-25-homo-5β-cholan-25-oate (25b);
tert-Butyl 3-aza-7β-hydroxy-25-homo-5β-cholan-25-oate (27b);
3-Aza-7β-hydroxy-25-homo-5β-cholan-25-oic acid (28b);
tert-Butyl N-methyl-3-aza-7β-hydroxy-25-homo-5β-cholan-25-oate (29b);
N-Methyl-3-aza-7β-hydroxy-25-homo-5β-cholan-25-oic acid (31b);
tert-Butyl N-glycolyl-3-aza-7β-hydroxy-25-homo-5β-cholan-25-oate (34b);
N-Glycolyl-3-aza-7β-hydroxy-25-homo-5β-cholan-25-oic acid (40b);
N-[(2S)-2-Amino-3-methylbutanoyl]-3-aza-7β-hydroxy-25-homo-5β-cholan-25-oic acid (41b);
N-[(2S,3S)-2-Amino-3-methylpentanoyl]-3-aza-7β-hydroxy-25-homo-5β-cholan-25-oic acid (42b);
N-[(2S)-2-Amino-4-methylpentanoyl]-3-aza-7β-hydroxy-25-homo-5β-cholan-25-oic acid (43b, Example 25);
N-[(2S)-2-Amino-3-(1H-indol-3-yl)propanoyl]-3-aza-7β-hydroxy-25-homo-5β-cholan-25-oic acid (44b);
N-(benzyloxycarbony)-3-aza-7β-hydroxy-5β-cholan-24-oic acid (50a);
N-(3-Aza-7β-hydroxy-5β-cholan-24-amide)-ethylsulfonic acid (51a);
N-(3-Aza-7β-hydroxy-5β-cholan-24-amide)-acetic acid (52a);
N-(3-Methyl-aza-7β-hydroxy-5β-cholan-24-oyl)-(2S)-2-amino-3-[(2-methylpropan-2-yl)oxy]propanoic acid (53a);
N-(3-Methyl-aza-7β-hydroxy-5β-cholan-24-oyl)-(R)-3-amino-3-phenylpropanoic acid (54a);
N-(3-Methyl-aza-7β-hydroxy-5β-cholan-24-oyl)-1-amino-4-fluorobenzene (55a);
N-(3-Aza-7β-hydroxy-5β-cholan-24-oyl)-morpholine (56a);
N-(3-Aza-7β-hydroxy-5β-cholan-24-oyl)-(S)-2-amino-3-hydroxypropanoic acid (57a);
N-(3-Aza-7β-hydroxy-5β-cholan-24-oyl)-3-amino-2-fluoropropanoic acid (58a);
N-(Cyclohexyl)-N-(3-methyl-aza-7β-hydroxy-5β-cholan-24-oyl)-cyclohexanamine (59a);
N-(3-Aza-7β-hydroxy-5β-cholan-24-oyl)-4-aminobenzoic acid (60a);
N-(3-Aza-7β-hydroxy-5β-cholan-24-oyl)-(S)-2-amino-4-(methylthio)butanoic acid (61a);
N-(3-Aza-7β-hydroxy-5β-cholan-24-amide)-propanoic acid (62a);
N-(3-Aza-7β-hydroxy-5β-cholan-24-oyl)-(isopropyl-4-aminobenzoate) (63a);
S-(3-Aza-7β-hydroxy-5β-cholan-24-oyl)-phenylmethanethiol (64a);
N-(3-Aza-7β-hydroxy-5β-cholan-24-oyl)-(S)-2-amino-3-methylbutanoic acid (65a);
N-(3-Aza-7β-hydroxy-5β-cholan-24-oyl)-(2S,3S)-2-amino-3-methylpentanoic acid (66a);
N-Methyl-N-(3-aza-7β-hydroxy-5β-cholan-24-oyl)-glycine (67a);
N-(3-Aza-7β-hydroxy-5β-cholan-24-oyl)-(S)-2-aminopropanoic acid (68a);
N-(benzyloxycarbonyl)-3-aza-7β-hydroxy-24-homo-5β-cholan-25-oic acid (50b);
N-(3-Aza-7β-hydroxy-27-homo-5β-cholan-27-oyl)-(S)-2-aminobutanedioic acid (70b);
N-(3-Aza-7β-hydroxy-27-homo-5β-cholan-27-oyl)-(2S)-2-amino-3-[(2-methylpropan-2-yl)oxy]propanoic acid (71b);
N-(3-Aza-7β-hydroxy-27-homo-5β-cholan-27-amide)-ethylsulfonic acid (72b);
N-(3-Aza-7β-hydroxy-27-homo-5β-cholan-27-oyl)-(S)-2-amino-3-phenylpropanoic acid (73b);
N-(3-Aza-7β-hydroxy-27-homo-5β-cholan-27-oyl)-3-aminobutanoic acid (74b);
N-(3-Aza-7β-hydroxy-27-homo-5β-cholan-27-oyl)-(S)-2-amino-4-methylpentanoic acid (75b);
N-(3-Aza-7β-hydroxy-27-homo-5β-cholan-27-oyl)-(2S)-2,6-diaminohexanoic acid (76b);
N-(3-Aza-7β-hydroxy-27-homo-5β-cholan-27-oyl)-(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid (77b);
N-{(benzyloxycarbonyl)-3-aza-7β-hydroxy-5β-cholan-24-oyl}-2-oxa-6-azospiro{3,3}heptane (78a);
N-{(benzyloxycarbonyl)-3-aza-7β-hydroxy-5β-cholan-24-oyl}-4-piperidone (79a);
N-{(benzyloxycarbonyl)-3-aza-7β-hydroxy-25-homo-5β-cholan-25-oyl}-3-aminotetrahydrofuran (80b);
N-{(3-aza-7β-hydroxy-5β-cholan-25-oyl}-isoindoline (81a);
N-{(3-aza-7β-hydroxy-25-homo-5β-cholan-25-oyl)}-3-aminotetrahydrofuran (82b); and
salts and solvates thereof.

### Claim 116 (depends on 94)

A method of preparing a compound of formula (I) or a salt or solvate thereof according to claim 94, the method comprising:
A. for a compound of formula (I) in which R1 is C(O)OR5 and R3 is C(O)OR16:
reacting a compound of formula (II):
wherein
R2 is selected from O and OH, wherein when R2 is O, is a double bond and when R2 is OH, is a single bond;
n is 1 or 2;
R1a is C(O)OR5 wherein R5 is C1-6 alkyl optionally substituted with one or more substituents selected from OR14a, N(R14a)(R14b), NH3+, C(O)N(R14a)(R14b), SR14 a 5- or 6-membered nitrogen-containing heterocyclic ring and a 6- to 14-membered aryl or 5- to 14-membered heteroaryl, wherein the aryl and heteroaryl are optionally substituted with one or more substituents selected from OH, halo, NH2, NO2, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(C1-6 alkyl) and O(C1-6 haloalkyl); and
R14a and R14b are each independently selected from H and C1-6 alkyl;
and R3a is C(O)OR16, wherein R16 is selected from C1-8 alkyl optionally substituted with one or more substituents selected from OH, halo and phenyl, wherein phenyl is optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(C1-6 alkyl) O(C1-6 haloalkyl), O(R15a), N(R15a)(R15b) and C(O)N(R15a)(R15b);
wherein R15a and R15b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl;
with methane sulfonyl chloride in an organic solvent at about −5° to 5° C.;
B. for a compound of formula (I) in which R1 is H:
hydrogenation of a compound of formula (I) in which R1 is C(O)OR5 over a palladium catalyst;
C. for a compound of formula (I) in which R1 is C1-6 alkyl and R3 is C(O)OR16:
reaction of a compound of formula (I) in which R1 is H and R3 is C(O)OR16 with a compound of formula (XX):
R1b—C(O)H (XX)
wherein R1b is C1-5 alkyl;
followed by hydrogenation over a palladium/carbon catalyst;
D. for a compound of formula (I) in which R1 is C2-6 alkenyl or C2-6 alkynyl and R3 is C(O)OR16:
reaction compound of formula (I) in which R1 is H and R3 is C(O)OR16 with a compound of formula (XVIII):
wherein R1c is C2-6 alkenyl or C2-6 alkynyl and X is chloro or bromo;
in the presence of a base;
wherein when R2 is OH, the method further comprises the initial step of protecting R2 with a suitable protecting group and the final step of removing the protecting group;
E. for a compound in which R3 is C(O)OH:
acid or base hydrolysis of a compound of formula (I) in which R3 is C(O)OR16;
F. for a salt of formula (I) in which the nitrogen atom to which R1 is attached is quaternised:
treatment of a compound of formula (I) in which R1 is H with an acid.
G. for a compound of formula (I) in which R1 is C(O)R4 and R3 is C(O)OR16:
i. reaction of a compound of formula (I) in which R1 is H and R3 is C(O)OR16 with a compound of formula (XXI):
wherein R4′ is C1-6 alkyl optionally substituted with one or more substituents selected from OR14a, N(R14a)(R14b), NH3+, C(O)N(R14a)(R14b), SR14 a protected OH group, a protected NH2 group, a protected C(O)NH2 group, a 5- or 6-membered nitrogen-containing heterocyclic ring and a 6- to 14-membered aryl or 5- to 14-membered heteroaryl, wherein the aryl and heteroaryl are optionally substituted with one or more substituents selected from OH, halo, NH2, NO2, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(C1-6 alkyl) and O(C1-6 haloalkyl);
under basic conditions, and in the presence of a coupling reagent; and
ii. where necessary, removal of a protecting group to give a group R4 comprising an OH, NH2 or C(O)NH2;
H. for a compound of formula (I) in which R1 is C(O)R4 and R3 is C(O)OH:
reaction of the product of G(i) with trifluoroacetic acid;
I. for a compound of formula (I) in which R3 is C(O)N(R6)—X1—R7:
reaction of a compound of formula (I) in which R3 is C(O)OH with a compound of formula (XXV):
wherein
X1 is C1-6 alkylene optionally substituted with one or more substituents selected from halo, OR12a, SR12a, N(R12a)(R12b) C(O)OR12a, C(O)N(R12a)(R12b), N(R12a)—C(NH)—N(R12a)(R12b), N(R12a)—C(N+H2)—N(R12a)(R12b) and 6- to 14-membered aryl or 5- to 14-membered heteroaryl, wherein aryl and heteroaryl groups are optionally substituted with one or more substituents selected from halo, C1-6 alkyl, C1-6 haloalkyl OR13a, N(R13a)(R13b), NO2, S(O)2OH, and CN;
R12a and R12b are each independently selected from H and C1-6 alkyl;
R13a and R13b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl;
R6 is selected from H, methyl and ethyl;
R7 is selected from C(O)OH, C(O)O—(C1-6 alkyl), S(O)2OH, and S(O)2—O—(C1-6 alkyl);
in the presence of a coupling reagent and under basic conditions, for example in the presence of an amine selected from diisopropylethylamine (DIPEA) or triethylamine (TEA) and in an organic solvent;
J. for a compound of formula (I) in which R3 is C(O)N(R8)(R9):
reaction of a compound formula (I) in which R3 is C(O)OH with a compound of formula (XXVI):
where:
R8 is selected from H, C1-6 alkyl and a 3- to 6-membered carbocyclyl group optionally substituted with one or more substituents selected from C1-6 alkyl, OH, O—(C1-6 alkyl), N(R19a)(R19b), C1-6 haloalkyl and halo;
wherein R19a and R19b are each independently selected from H and C1-6 alkyl;
R9 is selected from H, C1-6 alkyl, a 3- to 7-membered carbocyclyl group, a 3- to 7-membered heterocyclyl group, 6- to 14-membered aryl and 5- to 14-membered heteroaryl;
wherein alkyl groups are optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), C1-4 haloalkyl, O—(C1-4 haloalkyl), halo, N(R19a)(R19b), phenyl, 3- to 7-membered carbocyclyl and 3- to 7-membered heterocyclyl;
wherein R19a and R19b are each independently as defined above;
wherein carbocyclyl and heterocyclyl groups are optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), C1-4 haloalkyl, O—(C1-4 haloalkyl), oxo, phenyl, benzyl and halo, provided that heteroatoms of a heterocyclyl group are not substituted with OH, O—(C1-4 alkyl) or O—(C1-4 haloalkyl); and
wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b), C(O)N(R15a)(R15b), C(O)OH and C(O)O—(C1-6 alkyl);
wherein R15a and R15b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl; or
R8 and R9 together with the nitrogen atom to which they are attached combine to form a 4- to 10-membered heterocyclic group, optionally containing one or more further heteroatoms selected from O, N and S and optionally substituted with one or more substituents selected from C1-4 alkyl, OH, O—(C1-4 alkyl), halo, C1-4 haloalkyl, O—(C1-4 haloalkyl), C(O)OH, C(O)O(C1-4 alkyl), phenyl, benzyl, CN, N(R15a)(R15b), C(O)N(R15a)(R15b) and oxo provided that heteroatoms of a heterocyclyl group are not substituted with CN, N(R15a)(R15b), OH, O—(C1-4 alkyl) or O—(C1-4 haloalkyl);
wherein alkyl groups are optionally substituted by one or more groups selected from O—(C1-4 alkyl), O—(C1-4 haloalkyl), N(R15a)(R15b), OH and C3-6 cycloalkyl; or
R8 and R9 together with the nitrogen atom to which they are attached combine to form a 5- to 10-membered heteroaryl group optionally containing one or more further heteroatoms selected from N, O and S and optionally substituted with one or more substituents selected halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b), C(O)OH, C(O)N(R15a)(R15b) and C(O)O—(C1-5 alkyl);
wherein R15a and R15b are each independently as defined above;
wherein alkyl groups are optionally substituted by one or more groups selected from OH and C3-6 cycloalkyl;
wherein when the heteroaryl group contains a non-aromatic ring, the non-aromatic ring may also be substituted with oxo;
under basic conditions and in the presence of a coupling agent;
K. for a compound of formula (I) in which R8 and R9 together with the nitrogen atom to which they are attached combine to form a 5-membered heteroaryl ring:
coupling reaction of a compound of formula (I) in which R3 is C(O)N(R8)(R9), where R8 and R9 together with the nitrogen atom to which they are attached combine to form a 5- or 6-membered heterocyclic ring substituted with oxo;
L. for a compound of formula (I) in which R3 is C(O)S—R10:
reaction of a compound formula (I) in which R3 is C(O)OH with a compound of formula (XXVII):
where R10 is C1-6 alkyl optionally substituted with OH, halo or phenyl, wherein phenyl is optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(R15a), N(R15a)(R15b) and C(O)N(R15a)(R15b);
wherein R15a and R15b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl.

### Claim 117 (depends on 94)

A method for the treatment or prevention of a neurodegenerative disorder, acute radiation syndrome or myalgic encephalomyelitis (ME, chronic fatigue syndrome) or post viral syndrome, including chronic symptoms arising from infection with SARS-CoV2 (long COVID), the method comprising administering to a patient in need of such treatment an effective amount of a compound, salt or solvate according to claim 94.

### Claim 118 (depends on 94)

A pharmaceutical composition comprising a compound, salt or solvate according to claim 94, and a pharmaceutically acceptable excipient or carrier.

### Claim 119 (depends on 118)

A pharmaceutical composition according to claim 118, formulated for parenteral administration, oral administration topical administration to the skin (transdermal administration) or topical administration to the lung (by inhalation).

### Claim 120

A compound of formula (II):
wherein R2 is selected from O and OH, wherein when R2 is O, is a double bond and when R2 is OH, is a single bond, n is 1 or 2, R1a is C(O)OR5 and R3a is C(O)OR16, wherein R5 is C1-6 alkyl optionally substituted with one or more substituents selected from OR14a, N(R14a)(R14b), NH3+, C(O)N(R14a)(R14b), SR14 a 5- or 6-membered nitrogen-containing heterocyclic ring and a 6- to 14-membered aryl or 5- to 14-membered heteroaryl, wherein the aryl and heteroaryl are optionally substituted with one or more substituents selected from OH, halo, NH2, NO2, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(C1-6 alkyl) and O(C1-6 haloalkyl, and R16 is selected from C1-8 alkyl optionally substituted with one or more substituents selected from OH, halo and phenyl, wherein phenyl is optionally substituted with one or more substituents selected from halo, NO2, CN, S(O)2OH, C1-6 alkyl, C1-6 haloalkyl, O(C1-6 alkyl) O(C1-6 haloalkyl), O(R15a), N(R15a)(R15b) and C(O)N(R15a)(R15b);
wherein R15a and R15b are each independently selected from H, C1-6 alkyl and C1-6 haloalkyl; or
a compound of formula (IP2):
wherein R2 is selected from O and OH, wherein when R2 is O, is a double bond and when R2 is OH, is a single bond, n is 1 or 2, R3a is as defined for formula (II) above and R4a is C1-6 alkyl substituted with a protected NH2 group, a protected OH group or a protected C(O)NH2 group.
